CA2067235A1 - Modified biological material - Google Patents

Modified biological material

Info

Publication number
CA2067235A1
CA2067235A1 CA002067235A CA2067235A CA2067235A1 CA 2067235 A1 CA2067235 A1 CA 2067235A1 CA 002067235 A CA002067235 A CA 002067235A CA 2067235 A CA2067235 A CA 2067235A CA 2067235 A1 CA2067235 A1 CA 2067235A1
Authority
CA
Canada
Prior art keywords
species
complement
tissue
cells
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002067235A
Other languages
English (en)
French (fr)
Inventor
David J. G. White
Alan F. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imutran Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2067235(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898922987A external-priority patent/GB8922987D0/en
Priority claimed from GB909017198A external-priority patent/GB9017198D0/en
Application filed by Individual filed Critical Individual
Publication of CA2067235A1 publication Critical patent/CA2067235A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
CA002067235A 1989-10-12 1990-10-12 Modified biological material Abandoned CA2067235A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898922987A GB8922987D0 (en) 1989-10-12 1989-10-12 Modified biological material
GB8922987.6 1989-10-12
GB9017198.4 1990-08-06
GB909017198A GB9017198D0 (en) 1990-08-06 1990-08-06 Modified biological material

Publications (1)

Publication Number Publication Date
CA2067235A1 true CA2067235A1 (en) 1991-04-13

Family

ID=26296038

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002067235A Abandoned CA2067235A1 (en) 1989-10-12 1990-10-12 Modified biological material

Country Status (27)

Country Link
US (1) US6495735B1 (enExample)
EP (2) EP0709459A3 (enExample)
JP (1) JP3302358B2 (enExample)
KR (2) KR100317106B1 (enExample)
CN (2) CN1491624A (enExample)
AT (1) ATE139562T1 (enExample)
AU (1) AU654116B2 (enExample)
BG (1) BG61080B1 (enExample)
CA (1) CA2067235A1 (enExample)
CY (1) CY1996A (enExample)
DE (2) DE495852T1 (enExample)
DK (1) DK0495852T3 (enExample)
ES (1) ES2060561T3 (enExample)
FI (1) FI921618A0 (enExample)
GR (2) GR940300004T1 (enExample)
HK (1) HK48497A (enExample)
HU (1) HUT64584A (enExample)
IE (1) IE75345B1 (enExample)
IL (2) IL95970A0 (enExample)
IN (1) IN171948B (enExample)
MY (1) MY107433A (enExample)
NO (2) NO303502B1 (enExample)
NZ (2) NZ235657A (enExample)
PT (2) PT95580B (enExample)
RO (1) RO109863B1 (enExample)
SG (1) SG72614A1 (enExample)
WO (1) WO1991005855A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
EP0483247A4 (en) * 1989-07-21 1992-12-09 Washington University Recombinantly produced human membrane cofactor protein (mcp)
US5846715A (en) * 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
EP0537171B1 (en) * 1990-05-11 2002-09-18 The Austin Research Institute CD46 isoforms
JPH06506604A (ja) * 1991-07-15 1994-07-28 オクラホマ メディカル リサーチ ファウンデーション 自在なドナー細胞
US6916654B1 (en) * 1992-06-29 2005-07-12 Oklahoma Medical Research Foundation Universal donor cells
WO1994006903A1 (en) * 1992-09-22 1994-03-31 Dnx Biotherapeutics, Inc. Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
CA2196311A1 (en) * 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
WO1997006241A1 (en) 1995-08-04 1997-02-20 The General Hospital Corporation Transgenic swine and swine cells having human hla genes
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
AU1933897A (en) * 1996-03-22 1997-10-17 Imutran Limited Surfaces which prevent or reduce complement activation
ES2513043T3 (es) 1997-03-26 2014-10-24 Imperial Innovations Limited Proteína de fusión anticoagulante anclada a membrana de la célula
CA2297105A1 (en) 1997-07-14 1999-01-28 Nippon Meat Packers, Inc. Transgenic mammals
DE69828615T2 (de) * 1997-10-31 2005-12-01 Walter Reed Army Institute Of Research Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
SE523817C2 (sv) * 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
AU2004259019B2 (en) 2003-07-21 2010-09-23 Lifecell Corporation Acellular tissue matrices made from galactose alpha-1,3-galactose-deficient tissue
KR20180036810A (ko) 2009-08-14 2018-04-09 레비비코르 인코포레이션 당뇨병 치료를 위한 복수 형질전환 돼지
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
EP2675901B1 (en) 2011-02-14 2018-05-30 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
ES2846758T3 (es) 2013-11-04 2021-07-29 Lifecell Corp Métodos para eliminar la alfa-galactosa
CN114686427B (zh) * 2022-05-23 2022-07-29 中国人民解放军总医院第一医学中心 一种脾脏调节型b淋巴细胞及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081570A4 (en) * 1981-06-12 1985-09-02 Univ Ohio GENETIC TRANSFORMATION OF ZYGOTS.
US4431636A (en) 1982-05-24 1984-02-14 American Cyanamid Company Bis(4-O-polyhexaose-thio)-phenyl ureas and method of use
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
JPS62104594A (ja) * 1985-10-31 1987-05-15 Terumo Corp クエン酸塩利用能検査用培地組成物
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
DE3830271A1 (de) 1988-09-06 1990-03-15 Goetze Otto Mittel mit immunsuppressiver wirkung
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59

Also Published As

Publication number Publication date
PT95580B (pt) 1999-05-31
FI921618L (fi) 1992-04-10
NO982131L (no) 1992-04-10
PT95580A (pt) 1991-09-13
IE75345B1 (en) 1997-08-27
EP0495852B1 (en) 1996-06-19
DK0495852T3 (da) 1996-07-15
EP0495852A1 (en) 1992-07-29
IL120795A0 (en) 1997-09-30
FI921618A7 (fi) 1992-04-10
JP3302358B2 (ja) 2002-07-15
GR3020741T3 (en) 1996-11-30
NO921438L (no) 1992-04-10
HK48497A (en) 1997-04-25
WO1991005855A1 (en) 1991-05-02
IL95970A0 (en) 1992-05-25
MY107433A (en) 1995-12-30
IE903649A1 (en) 1991-04-24
FI921618A0 (fi) 1992-04-10
US6495735B1 (en) 2002-12-17
SG72614A1 (en) 2000-05-23
JPH05503074A (ja) 1993-05-27
DE69027535D1 (de) 1996-07-25
CN1491624A (zh) 2004-04-28
NZ235657A (en) 1994-05-26
ATE139562T1 (de) 1996-07-15
AU6539290A (en) 1991-05-16
AU654116B2 (en) 1994-10-27
PT101896B (pt) 2003-01-31
CN1051199A (zh) 1991-05-08
IN171948B (enExample) 1993-02-13
KR920702410A (ko) 1992-09-04
EP0709459A2 (en) 1996-05-01
NO303502B1 (no) 1998-07-20
HUT64584A (en) 1994-01-28
KR100317106B1 (ko) 2001-12-22
DE69027535T2 (de) 1996-11-28
RO109863B1 (ro) 1995-06-30
HU9201240D0 (en) 1992-06-29
EP0709459A3 (en) 1999-01-07
GR940300004T1 (en) 1994-02-28
ES2060561T3 (es) 1996-08-01
NO921438D0 (no) 1992-04-10
DE495852T1 (de) 1994-03-31
BG61080B1 (bg) 1996-10-31
CN1122719C (zh) 2003-10-01
NZ248153A (en) 1997-07-27
PT101896A (pt) 1998-02-27
ES2060561T1 (es) 1994-12-01
CY1996A (en) 1997-09-05
BG96329A (bg) 1993-12-24
NO982131D0 (no) 1998-05-11

Similar Documents

Publication Publication Date Title
EP0495852B1 (en) Modified biological material
US5849288A (en) Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
CA2163517C (en) Surrogate tolerogenesis for the development of tolerance to xenografts
US6482404B1 (en) Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
Barnes et al. The disease of the NZB mouse. I. Examination of ovum fusion-derived tetraparental NZB: CFW chimaeras
RU2252533C2 (ru) Способ получения трансгенного животного
Geissler et al. Effective use of donor MHC class I gene therapy in organ transplantation: prevention of antibody-mediated hyperacute heart allograft rejection in highly sensitized rat recipients
White et al. The control of hyperacute rejection by genetic engineering of the donor species
CA2213669A1 (en) Transgenic animals as model of psoriasis
US5620881A (en) Gene encoding mutant L3T4 protein which facilitates HIV infection and transgenic mouse expressing such protein
AU671158B2 (en) Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
WO1994006903A9 (en) Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
US20240002486A1 (en) Anti-thymocyte globulin
Ivanyi et al. The major histocompatibility system of cattle, pig, rabbit, and Syrian hamster
Tomayko Regulation of A1 gene expression during B and T lymphocyte differentiation
Trawick Characterization of recombinant class I MHC alloantigen action upon the survival of disparate heart allografts
Kollmann Of man in mice: Human-mouse chimeras as in vivo model systems for studying human hematopoiesis, immunology and HIV infection
Zheng Control of murine hemopoietic histocompatibility by class I MHC molecules

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued